Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2006.05.8198 on August 8 2006

Journal of Clinical Oncology, Vol 24, No 25 (September 1), 2006: pp. 4143-4149
© 2006 American Society of Clinical Oncology.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Press, O. W.
Right arrow Articles by Fisher, R. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Press, O. W.
Right arrow Articles by Fisher, R. I.

Phase II Trial of CHOP Chemotherapy Followed by Tositumomab/Iodine I-131 Tositumomab for Previously Untreated Follicular Non-Hodgkin's Lymphoma: Five-Year Follow-Up of Southwest Oncology Group Protocol S9911

Oliver W. Press, Joseph M. Unger, Rita M. Braziel, David G. Maloney, Thomas P. Miller, Michael LeBlanc, Richard I. Fisher

From the Fred Hutchinson Cancer Research Center; Southwest Oncology Group Statistical Center, Seattle, WA; Oregon Health Sciences University, Portland, OR; Arizona Cancer Center, University of Arizona, Tucson, AZ; and the James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY

Address reprint requests to Southwest Oncology Group (S9911), Operations Office, 14980 Omicron Dr, San Antonio, TX 78245-3217; e-mail: pubs{at}swog.org


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 Authors' Disclosures of...
 Author Contributions
 REFERENCES
 
Purpose: Advanced follicular lymphoma (FL) is incurable with conventional chemotherapy and radiotherapy, and optimal front-line management is controversial. This study was performed to determine the efficacy of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy followed by tositumomab/iodine I-131 tositumomab.

Patients and Methods: From 1999 to 2000, the Southwest Oncology Group (SWOG) conducted a phase II trial (S9911) to test a novel new regimen consisting of six cycles of CHOP chemotherapy followed 4 to 8 weeks later by tositumomab/iodine I-131 tositumomab in 90 eligible patients with previously untreated, advanced-stage FL.

Results: The overall response rate was 91%, including a 69% complete remission (CR) rate. After a median follow-up time of 5.1 years, the estimated 5-year overall survival (OS) rate was 87%, and the progression-free survival (PFS) rate was 67%. The 5-year estimates of OS and PFS were each 23% better (absolute difference) than the corresponding figures for patients treated on previous SWOG protocols with CHOP alone. An analysis according to the Follicular Lymphoma International Prognostic Index showed that 21% of patients had high-risk features, 44% had intermediate-risk features, and 34% had low-risk features. High-risk patients had worse OS than lower risk patients (P = .05), but differences in PFS were not statistically significant (P = .21). Serial monitoring of the t(14;18) translocation in bone marrow by polymerase chain reaction demonstrated that 32 of 38 informative patients obtained molecular CRs, including seven patients (18%) after CHOP and 24 additional patients (63%) after tositumomab/iodine I-131 tositumomab. (The timing of conversion of one patient was unclear.)

Conclusion: A prospective, phase III, randomized Intergroup Trial is currently underway comparing the efficacy of the promising CHOP + tositumomab/iodine I-131 tositumomab regimen with the efficacy of CHOP + rituximab.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 Authors' Disclosures of...
 Author Contributions
 REFERENCES
 
Follicular lymphoma (FL) affects approximately 15,000 Americans annually and is the second most common type of non-Hodgkin's lymphoma in the United States. FL usually progresses slowly but inexorably, with a median survival time of 7 to 10 years after diagnosis.1-3 A Follicular Lymphoma International Prognostic Index (FLIPI) based on five clinical parameters has recently been delineated that is capable of stratifying patients treated with conventional therapies into low-, intermediate-, and high-risk subgroups with median survival times of 10, 7, and 5 years, respectively.4 Despite initial responsiveness to multiple treatments, there is currently no convincing evidence that any conventional therapy is curative for patients with advanced FL. Experts differ greatly in their opinions regarding optimal front-line management of patients with FL, resulting in a diverse menu of treatment recommendations including watchful waiting; chlorambucil; rituximab; cyclophosphamide, vincristine, and prednisone (CVP); fludarabine-based regimens; and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Recent randomized studies have convincingly demonstrated that the addition of rituximab to CVP, CHOP, and fludarabine-based regimens improves the overall response rates, complete remission (CR) rates, and event-free survival compared with the same regimens administered without rituximab.5-7 Whether such combined immunochemotherapy regimens also improve overall survival (OS) of FL patients is controversial, although recent evidence suggests that this may be the case.6,8,9

In the past few years, radiolabeled anti-CD20 antibodies have been introduced to improve the efficacy of antibody therapy for B-cell lymphomas. Studies with tositumomab/iodine I-131 tositumomab (Bexxar; GlaxoSmithKline, Philadelphia, PA) and yttrium-90 ibritumomab tiuxetan (Zevalin; Biogen Idec, Cambridge, MA) have demonstrated their safety and efficacy, with multiple trials demonstrating overall response rates of 50% to 80% and CR rates of 20% to 40% in patients with relapsed or refractory FL.10-16 Both products are now approved by the Food and Drug Administration for treatment of patients with relapsed, refractory, or transformed FL, but their role in front-line therapy is uncertain.

In May 1999, the Southwest Oncology Group (SWOG) opened a phase II study (S9911) of multimodality therapy using six cycles of CHOP chemotherapy followed by consolidation with tositumomab/iodine I-131 tositumomab for patients with previously untreated advanced FL to determine whether administering this novel combination was feasible, safe, and effective. An initial report detailing the toxicities, response rates, and 2-year progression-free survival (PFS) has been previously published.17 We now report more mature safety and efficacy results with a median follow-up time of 5.1 years. Furthermore, we present here, for the first time, outcome according to FLIPI prognostic analysis, molecular remission rates after CHOP and after tositumomab/iodine I-131 tositumomab determined by serial polymerase chain reaction (PCR) for the t(14;18) translocation in bone marrow, and a comparison of the results of S9911 with SWOG's historical CHOP studies in FL.


   PATIENTS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
RESULTS
 DISCUSSION
 Authors' Disclosures of...
 Author Contributions
 REFERENCES
 
Eligibility
Patients with biopsy-proven, CD20-positive, untreated FL of any grade (1, 2, or 3) were eligible if they were over the age of 18 years, had bidimensionally measurable bulky stage II, stage III, or stage IV disease, a SWOG performance status of 0 to 2, a pretreatment granulocyte count ≥ 1,500 cells/µL, and a platelet count ≥ 100,000/µL. All diagnostic biopsies were reviewed centrally by expert pathologists of the SWOG. Exclusion criteria are defined in the initial publication.17 All patients signed a written informed consent in accordance with institutional and federal guidelines.

FLIPI Risk Stratification
The FLIPI was not defined at the time this study was conducted, but we reviewed the flow sheets and case report forms for all 90 eligible patients between October 2005 and December 2005 to assign FLIPI scores according to the published criteria.4

Protocol Treatment
Patients were treated with standard CHOP chemotherapy every 21 days for six cycles.17 Patients achieving at least an unconfirmed partial response (PR)18 after six cycles of CHOP chemotherapy were eligible for consolidation with tositumomab/iodine I-131 tositumomab using the standard regimen developed by Kaminski et al.10,19 Thyroid protection was provided with Lugol's solution.17 Full details of the treatment regimen and dose modification guidelines are available in the initial publication. Human antimouse antibody testing was not performed in this study.

Assessment of Clinical Responses
Data were centrally reviewed, and clinical responses (PR, unconfirmed CR [CRu], or CR) were assigned by the SWOG statistical center according to the criteria of an international workshop.18 Remission status was recorded 4 weeks after the sixth cycle of CHOP (just before tositumomab/iodine I-131 tositumomab); then 8 weeks, 6 months, and 12 months after tositumomab/iodine I-131 tositumomab; at least annually thereafter; and whenever patients developed symptoms or signs of lymphoma by performing a medical history, physical examination, CBC with leukocyte differential, platelet count, abdominal and pelvic computed tomography (CT), chest radiograph or CT scan, and bone marrow aspiration and biopsy. Bone marrow cytogenetic studies were not required. Patients were removed from protocol treatment if they experienced progression of disease or unacceptable toxicity or declined protocol therapy.

Assessment of Molecular Responses
Patients were asked to undergo serial bone marrow aspirations at study entry, 4 weeks after the sixth cycle of CHOP (just before tositumomab/iodine I-131 tositumomab), and then 8 weeks, 6 months, and 12 months after tositumomab/iodine I-131 tositumomab for PCR testing. The mononuclear cell fraction was isolated from marrow aspirates by Ficoll-Hypaque sedimentation and cryopreserved for subsequent batch analysis using a double nested PCR assay to detect the major breakpoint region and the minor cluster region of the BCL2 gene using the method of Gribben.20,21 Samples were initially analyzed by fragment size using ethidium bromide gel electrophoresis of the PCR product and then transferred to nitrocellulose membranes for confirmation of the identity of the BCL2 translocation by Southern blotting. The adequacy of samples was demonstrated using beta-globin as a positive control housekeeping gene. Patients were considered to have attained a molecular remission if their marrow sample at study entry contained a detectable t(14;18) translocation that became undetectable after protocol treatment.

Statistical Considerations
The study was designed to enroll 80 eligible patients, which was a number sufficient to estimate the 2-year PFS rate (given complete follow-up) to within ± 11% (95% CI). Previous SWOG studies have shown a 2-year PFS rate of approximately 65% in this patient group. This design gives 86% power to detect a 15% difference in 2-year PFS. Eighty patients were also sufficient to estimate the best response rate to CHOP to within ± 11% (95% CI) and the probability of any toxicity to within 11%. Any adverse event occurring with at least 5% probability was likely to be seen at least once (98% chance). OS and PFS curves were plotted by the Kaplan-Meier method.22 PFS was defined as the time from registration to the first observation of progressive disease or death as a result of any cause. Analyses of survival differences by category were performed using Cox regression.23


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
DISCUSSION
 Authors' Disclosures of...
 Author Contributions
 REFERENCES
 
Patient Characteristics
The characteristics of the patients entered onto this study have been published previously.17 One hundred two patients were registered between May 15, 1999, and June 1, 2000, and 90 of these patients were eligible. Seven patients were ineligible as a result of insufficient submission of prestudy information, three patients did not have FL, one patient had the wrong stage, and one patient had a prior history of lymphoma. The median age of patients on the trial was 50 years (range, 23 to 84 years); 61% were male, 27% presented with "B" symptoms, 23% had bulky adenopathy (≥ 10 cm), 4% had stage II disease, 33% had stage III disease, and 63% had stage IV disease. Central pathologic review confirmed that 60%, 29%, and 11% of patients had grade 1, 2, and 3 FL, respectively.

Acute Toxicities
An updated analysis of acute toxicity data revealed only minor differences from the initial report (Table 1). There were no treatment-related deaths. One patient refused therapy after registration and was not assessable for CHOP toxicity. Of 89 patients assessable for CHOP toxicity, 35 patients (39%) experienced, at worst, grade 4 toxicity and 31 patients (35%) experienced, at worst, grade 3 events during chemotherapy. Three patients were not assessable for antibody therapy toxicity, one because of patient refusal and two others because of lack of follow-up data submission. Of 82 patients assessable for toxicities after tositumomab/iodine I-131 tositumomab, 10 (12%) experienced, at worst, grade 4 toxicity and 28 patients (34%) experienced, at worst, grade 3 events after tositumomab/iodine I-131 tositumomab.


View this table:
[in this window]
[in a new window]

  		Table 1. Grade 3 to 5 Acute Toxicities

 
Late Toxicities
Among the 90 eligible patients, eight patients (9%) developed documented elevated thyroid-stimulating hormone levels after protocol treatment, six patients (7%) were reported to have mild anemia 1 year or more after therapy (hemoglobin, 11.1 to 12.4 g/dL), three patients (3%) had mild leukopenia or neutropenia (neutrophil count < 1,500/µL) 1 year or more after therapy, and one patient had thrombocytopenia in association with myelodysplasia, which developed 1.4 years after registration. One patient (1%) developed deep venous thrombosis. Late cytopenias were all mild (grade 1 to 2), except for the patient who developed myelodysplasia. Three patients (3%) developed other second cancers, including one patient with both basal cell carcinoma (3.4 years after registration) and colon cancer (5.1 years after registration), one patient with lung cancer 4.7 years after registration, and one patient with breast cancer 2.7 years after registration. The ages of these three patients were 84, 58, and 60 years, respectively. There were no reported cases of acute myeloid leukemia (AML). The estimates of late hypothyroidism and cytopenias may represent underestimates of the true rates because the study was not initially designed to require recording of these late events. However, reporting of myelodysplastic syndrome (MDS), AML, and secondary cancers was mandatory.

Clinical Responses
Of the 90 eligible patients, six (7%) had insufficient documentation to assess response, 62 (69%) achieved CRs (CR or CRu), 20 (22%) achieved a PR, and two (2%) had stable disease. If response analysis is limited to the 84 patients for whom sufficient documentation is available to assess response, 98% had objective remissions, including 74% with CR (CR or CRu) and 24% with PR. Therapy with tositumomab/iodine I-131 tositumomab seemed to substantially improve the CR rate (from 39% after six cycles of CHOP to 69% after tositumomab/iodine I-131 tositumomab).

Assessment of Molecular Responses
Patients were asked to undergo five serial bone marrow aspirations for PCR (at study entry; at completion of six cycles of CHOP but before tositumomab/iodine I-131 tositumomab; and then 8 weeks, 6 months, and 12 months after tositumomab/iodine I-131 tositumomab). Of the 90 eligible patients, 25 patients lacked detectable levels of the t(14;18) translocation by PCR at study entry, either because their tumor did not express the translocation or because the marrow was uninvolved with disease. Of the remaining 65 patients, 27 patients did not have both baseline and serial bone marrow testing (as a result of patient or physician refusal), leaving 38 patients with informative marrow specimens. Of these 38 informative patients, 32 (84%) became PCR negative after protocol therapy. Seven patients (18%) converted to PCR negative after CHOP, and an additional 24 patients (63%) converted after tositumomab/iodine I-131 tositumomab. One patient (3%) converted to PCR negative, but attribution of PCR conversion to a particular phase of treatment was not possible because the marrow aspirate between CHOP and tositumomab/iodine I-131 tositumomab was missing. One of the 24 patients who converted to PCR negativity after tositumomab/iodine I-131 tositumomab subsequently reverted to being PCR positive on a later marrow sample.

PFS and OS
With a median follow-up time of 5.1 years, 31 of 90 eligible patients haven experienced progression or died, yielding an estimated 5-year PFS rate of 67% (Fig 1). Twelve eligible patients (13%) have died, 10 after a diagnosis of progressive lymphoma. One of the other two patients died of apparent myocardial infarction unrelated to treatment, and the other patient died of colon cancer. None of these deaths were considered related to the treatment administered on this protocol. The 5-year estimate of OS was 87% (Fig 1). Significant differences were not observed in either PFS or OS according to PCR status (data not shown), although power to detect differences was low.


Figure 1
View larger version (6K):
[in this window]
[in a new window]
[PowerPoint Slide for Teaching]
  		Fig 1. Progression-free and overall survival of 90 eligible patients with bulky stage II to stage IV follicular non-Hodgkin's lymphoma treated with six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy followed by tositumomab/iodine I-131 tositumomab. The 5-year estimate of overall survival is 87%, and the 5-year estimate of progression-free survival is 67%.

 
FLIPI Analysis
FLIPI had not been defined at the time that this study was conducted. Because lymphoma experts have recently emphasized the importance of reporting the composition of FL research trials using this index, we reviewed each patient's records and assigned FLIPI scores. Using the published criteria, 19 patients (21%) were in the FLIPI high-risk group, 40 patients (44%) were in the intermediate-risk group, and 31 patients (34%) were in the low-risk group (Table 2). There were no significant differences in PFS according to FLIPI prognostic category (P = .21, Fig 2). OS was progressively worse in the higher FLIPI risk groups (P = .05, Fig 3) but better in the intermediate- and high-risk groups than would have been predicted by prior publications using other regimens.4


View this table:
[in this window]
[in a new window]

  		Table 2. FLIPI Factors

 

Figure 2
View larger version (8K):
[in this window]
[in a new window]
[PowerPoint Slide for Teaching]
  		Fig 2. Progression-free survival of 90 eligible patients with bulky stage II to stage IV follicular non-Hodgkin's lymphoma treated with six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy followed by tositumomab/iodine I-131 tositumomab, stratified by Follicular Lymphoma International Prognostic Index category (low risk, 31 patients; intermediate risk, 40 patients; and high risk, 19 patients).

 

Figure 3
View larger version (7K):
[in this window]
[in a new window]
[PowerPoint Slide for Teaching]
  		Fig 3. Overall survival of 90 eligible patients with bulky stage II to stage IV follicular non-Hodgkin's lymphoma treated with six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy followed by tositumomab/iodine I-131 tositumomab, stratified by Follicular Lymphoma International Prognostic Index category (low risk, 31 patients; intermediate risk, 40 patients; and high risk, 19 patients).

 
Comparison of Outcome With Prior SWOG Trials
To determine whether the results obtained in this trial were sufficiently promising to conduct a randomized study using CHOP + tositumomab/iodine I-131 tositumomab as one of the experimental arms, we compared the PFS and OS observed on S9911 with the updated results for 356 FL patients treated on two prior trials (S7426 and S7713) conducted by the SWOG using CHOP without anti-CD20 antibodies (Figs 4 and 5). 24 Figures 4 and 5 demonstrate a 23% higher estimated PFS after 5 years for CHOP + tositumomab/iodine I-131 tositumomab compared with historical CHOP (67% v 44%, respectively; P = .001, adjusted for FLIPI) and a 23% higher OS for CHOP + tositumomab/iodine I-131 tositumomab compared with historical CHOP (87% v 64%, respectively; P = .0003, adjusted for FLIPI).


Figure 4
View larger version (6K):
[in this window]
[in a new window]
[PowerPoint Slide for Teaching]
  		Fig 4. Comparison of the progression-free survival (PFS) of 90 patients with bulky stage II to stage IV follicular non-Hodgkin's lymphoma treated with six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy followed by tositumomab/iodine I-131 tositumomab (radioimmunotherapy [RIT]) with the PFS of 356 similar patients treated on previous Southwest Oncology Group studies of CHOP without anti-CD20 antibodies (historical CHOP). Five-year estimates of PFS for each regimen are shown.

 

Figure 5
View larger version (6K):
[in this window]
[in a new window]
[PowerPoint Slide for Teaching]
  		Fig 5. Comparison of the overall survival (OS) of 90 patients with stage II to IV follicular non-Hodgkin's lymphoma treated with six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy followed by tositumomab/iodine I-131 tositumomab (radioimmunotherapy [RIT]) on the current trial (S9911) with the OS of 356 similar patients treated on previous studies with CHOP without anti-CD20 antibodies (historical CHOP). Five-year estimates of OS with each regimen are shown.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
Authors' Disclosures of...
 Author Contributions
 REFERENCES
 
This study has documented the feasibility, safety, and efficacy of administering six cycles of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab as primary therapy for patients with advanced FL. The updated results presented in this report with 5.1 years of median follow-up time are encouraging because they document the durability of the majority of responses, with a PFS rate of 67% at 5 years. OS also remains excellent, with 87% of patients alive after 5 years despite the fact that two thirds of the patients were in the intermediate- and high-risk FLIPI groups. The PCR data emphasize the efficacy of the combination used, demonstrating that molecular remissions were achieved after six cycles of CHOP chemotherapy in, at most, 21% of patients with informative PCR data, whereas 84% of these patients attained this status after tositumomab/iodine I-131 tositumomab.

The paucity of serious late toxicities in this trial is also encouraging. Delayed mild cytopenias were reported in only a small minority of patients, suggesting that bone marrow stem-cell reserve was preserved. Furthermore, the reported incidence of hypothyroidism was only 9%. Although these figures may underestimate the true rates of these events, the concordance between the rate of hypothyroidism reported on this trial (9%) and the rates published from other studies using the same dose of tositumomab/iodine I-131 tositumomab10 suggests that the data are reliable. The low incidences of MDS (1%) and AML (0%) after 5.1 years of follow-up are particularly reassuring because many investigators consider these sequelae to represent the greatest risks of radioimmunotherapy (RIT). The low incidence of MDS/AML after upfront RIT is supported by two other trials that have observed no cases of MDS/AML among 111 patients treated with tositumomab/iodine I-131 tositumomab as initial therapy.25,26 Second solid tumors were also uncommon in this study, with only four cancers reported in three patients (3%), which approximates the expected rate of solid tumor formation in the general population in this age group.27

In recent years, the efficacy and safety of RIT for relapsed, refractory, and transformed FL have been convincingly demonstrated for both tositumomab/iodine I-131 tositumomab and for yttrium-90 ibritumomab tiuxetan. However, the role of RIT in first-line therapy remains undefined. However, five trials using radiolabeled antibodies as front-line treatment of indolent non-Hodgkin's lymphoma have been recently reported, and all are extremely encouraging. Trials using tositumomab/iodine I-131 tositumomab alone25 or after CVP,28 fludarabine,26 or CHOP chemotherapy17 and a preliminary report of yttrium-90 ibritumomab tiuxetan after three cycles of rituximab + CHOP29 have reported overall response rates ranging from 90% to 100% and CR rates of 60% to 90%. Many of the remissions have persisted for more than 5 years, and toxicities have been manageable. Our study is notable for being the largest of the five reported trials (90 patients), has the longest follow-up time (5.1 years) and the highest reported 5-year PFS rate (67%), and is the only study to include grade 3 FL patients and to be conducted through a major cooperative group. Diagnostic biopsies from all eligible patients were centrally reviewed by expert hematopathologists on the SWOG trial to confirm the diagnosis of FL and the histologic grade. Furthermore, responses and remission durations were centrally assessed by the SWOG Statistical Center, not by investigators, to assure maximal objectivity. PCR assays were performed by an expert in molecular diagnostics at a central laboratory to assure standardized, uniform methodology.

The PFS and OS rates observed in this trial are the best ever observed in a study of FL conducted by the SWOG and represent a 23% improvement over historical experience for each parameter. Furthermore, the survival rates observed for the intermediate- and high-risk FLIPI subgroups appear substantially better than those predicted from previous publications.4 However, we recognize that such historical comparisons may be misleading because recent reports suggest better survival of FL patients in recent years, which has been attributed to improvements in supportive care, the availability of new agents (eg, maintenance rituximab),30,31 and better management of comorbid illnesses.8,9 It is also possible that these apparent differences might be a result of differences in patient characteristics or protocol eligibility criteria between the studies. Furthermore, it is conceivable that progression rates might have been impacted if more frequent monitoring with CT scans had been mandated by the protocol. Therefore, it is essential that new regimens, such as CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab, be compared with other regimens in rigorous, randomized, phase III trials before conclusions are reached about relative efficacy. Thus, we encourage FL patients and their physicians to participate in the ongoing Intergroup Trial S0016 being conducted jointly by SWOG, Cancer and Leukemia Group B (S0016), the Eastern Cooperative Oncology Group, and the Clinical Trial Support Unit, rather than to adopt this regimen based on favorable phase II results and historical comparisons. The randomized trial compares six cycles of CHOP administered concurrently with rituximab32 with the CHOP plus tositumomab/iodine I-131 tositumomab regimen described in this article. At the time of submission of this article, approximately 340 of the 500 planned patients had been enrolled.


   Authors' Disclosures of Potential Conflicts of Interest
TOP
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 Authors' Disclosures of...
Author Contributions
 REFERENCES
 
Although all authors completed the disclosure declaration, the following authors or their immediate family members indicated a financial interest. No conflict exists for drugs or devices used in a study if they are not being evaluated as part of the investigation. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.


Authors Employment Leadership Consultant Stock Honoraria Research Funds Testimony Other
Oliver W. Press Genentech (A); Biogen Idec (A); GlaxoSmithKline (A) Genentech (A)
David G. Maloney Biogen Idec (A); Genentech (A) Biogen Idec (A); Genentech (A) Genentech (B)
Richard I. Fisher GlaxoSmithKline (A) GlaxoSmithKline (A)

Dollar Amount Codes (A) < $10,000 (B) $10,000-99,999 (C) > $100,000 (N/R) Not Required


   Author Contributions
TOP
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 Authors' Disclosures of...
 Author Contributions
REFERENCES
 

Conception and design: Oliver W. Press, Joseph M. Unger, Rita M. Braziel, David G. Maloney, Thomas P. Miller, Michael LeBlanc, Richard I. Fisher

Provision of study materials or patients: Oliver W. Press, Thomas P. Miller, Richard I. Fisher

Collection and assembly of data: Oliver W. Press, Joseph M. Unger, Rita M. Braziel, Thomas P. Miller, Michael LeBlanc

Data analysis and interpretation: Oliver W. Press, Joseph M. Unger, Rita M. Braziel, David G. Maloney, Thomas P. Miller, Michael LeBlanc, Richard I. Fisher

Manuscript writing: Oliver W. Press, Joseph M. Unger, Rita M. Braziel, David G. Maloney, Thomas P. Miller, Richard I. Fisher

Final approval of manuscript: Oliver W. Press, Joseph M. Unger, Thomas P. Miller, Michael LeBlanc, Richard I. Fisher

 


   ACKNOWLEDGMENTS
 
We thank Scott Kurruk, Jill Loveland, Michelle Ward, and the Operations and Statistical Offices of the Southwest Oncology Group for their administrative assistance with the conduct of this trial and the preparation of this manuscript. In addition, we acknowledge the generous support of GlaxoSmithKline Inc, who provided tositumomab and iodine I-131 tositumomab for this trial and a research grant covering the Nuclear Medicine costs.


   NOTES
 
published online ahead of print at www.jco.org on August 7, 2006.

Supported in part by the following Public Health Service Cooperative Agreement Grants awarded by the National Cancer Institute, Department of Health and Human Services: CA38926, CA32102, CA46113, CA46282, CA20319, CA13612, CA11083, CA35261, CA35128, CA35192, CA37981, CA45377, CA67575, CA58861, CA35090, CA63844, CA35176, CA35996, CA46368, CA04919, CA46441, CA12644, CA58686, CA63850, CA35119, CA35431, CA58348, CA35281, CA76132, CA12213, CA76447, CA45560. Also supported in part by GlaxoSmithKline Inc.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 Authors' Disclosures of...
 Author Contributions
 REFERENCES
 
1. Rohatiner AZ, Lister TA: The clinical course of follicular lymphoma. Best Pract Res Clin Haematol 18:1-10, 2005[Medline]

2. Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes—Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16:2780-2795, 1998[Abstract]

3. Horning SJ: Treatment approaches to the low-grade lymphomas. Blood 83:881-884, 1994[Free Full Text]

4. Solal-Celigny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004[Abstract/Free Full Text]

5. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005[Abstract/Free Full Text]

6. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005[Abstract/Free Full Text]

7. Zinzani PL, Pulsoni A, Perrotti A, et al: Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 22:2654-2661, 2004[Abstract/Free Full Text]

8. Fisher RI, LeBlanc M, Press OW, et al: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:8447-8452, 2005[Abstract/Free Full Text]

9. Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019-5026, 2005[Abstract/Free Full Text]

10. Kaminski MS, Estes J, Zasadny KR, et al: Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259-1266, 2000[Abstract/Free Full Text]

11. Vose JM, Wahl RL, Saleh M, et al: Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18:1316-1323, 2000[Abstract/Free Full Text]

12. Davies AJ, Rohatiner AZ, Howell S, et al: Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 22:1469-1479, 2004[Abstract/Free Full Text]

13. Horning SJ, Younes A, Jain V, et al: Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23:712-719, 2005[Abstract/Free Full Text]

14. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1224, 1993[Abstract/Free Full Text]

15. Witzig TE, White CA, Wiseman GA, et al: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999[Abstract/Free Full Text]

16. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002[Abstract/Free Full Text]

17. Press OW, Unger JM, Braziel RM, et al: A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 102:1606-1612, 2003[Abstract/Free Full Text]

18. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:2454-2460, 1999[Abstract/Free Full Text]

19. Kaminski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19:3918-3928, 2001[Abstract/Free Full Text]

20. Gribben JG, Freedman AS, Neuberg D, et al: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325:1525-1533, 1991[Abstract]

21. Iqbal S, Jenner MJ, Summers KE, et al: Reliable detection of clonal IgH/Bcl2 MBR rearrangement in follicular lymphoma: Methodology and clinical significance. Br J Haematol 124:325-328, 2004[CrossRef][Medline]

22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958[CrossRef]

23. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972

24. Dana BW, Dahlberg S, Nathwani BN, et al: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993[Abstract]

25. Kaminski MS, Tuck M, Estes J, et al: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441-449, 2005[Abstract/Free Full Text]

26. Leonard JP, Coleman M, Kostakoglu L, et al: Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 23:5696-5704, 2005[Abstract/Free Full Text]

27. Edwards BK, Brown ML, Wingo PA, et al: Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97:1407-1427, 2005[Abstract/Free Full Text]

28. Link B, Kaminski MS, Coleman M, et al: Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma. J Clin Oncol 22:560a, 2004 (suppl, abstr 6520)[CrossRef]

29. Shipley DL, Greco FA, Spigel DR, et al: Rituximab with short duration chemotherapy followed by Y-90 ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: Update of a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 23:579, 2005 (suppl I; abstr 6577)

30. Van Oers MHJ, Glabbeke MV, Teodorovic I, et al: Chimeric anti-CD20 monoclonal antibody (rituximab; MabThera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Final analysis of a phase III randomized intergroup clinical trial. Blood 106:107a, 2005 (abstr 353)

31. Hochster HS, Weller E, Gascoyne RD, et al: Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Group and Cancer and Leukemia Group B. Blood 106:106a, 2005 (abstr 349)

32. Czuczman MS, Weaver R, Alkuzweny B, et al: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22:4711-4716, 2004[Abstract/Free Full Text]

Submitted February 3, 2006; accepted June 30, 2006.




This article has been cited by other articles:


Home page
 CA Cancer J ClinHome page
M. Bendandi
Aiming at a Curative Strategy for Follicular Lymphoma
CA Cancer J Clin, September 1, 2008; 58(5): 305 - 317.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
B. D. Cheson and J. P. Leonard
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
N. Engl. J. Med., August 7, 2008; 359(6): 613 - 626.
[Full Text] [PDF]

Home page
 The OncologistHome page
J. P. Plastaras, E. Glatstein, and S. J. Schuster
Commentary: Let the Tail Wag the Dog: The Case for Radioimmunotherapy of Low-Grade Follicular Lymphoma
Oncologist, June 1, 2008; 13(6): 655 - 656.
[Full Text] [PDF]

Home page
 The OncologistHome page
F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer
Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma
Oncologist, June 1, 2008; 13(6): 657 - 667.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
M. J. Bishton, R. J. Hicks, D. A. Westerman, M. H. Prince, M. Wolf, and J. F. Seymour
A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy
Haematologica, May 1, 2008; 93(5): 789 - 790.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. B. Thomas, J. P. O'Beirne, J. Furuse, A. T. C. Chan, G. Abou-Alfa, and P. Johnson
Systemic Therapy for Hepatocellular Carcinoma: Cytotoxic Chemotherapy, Targeted Therapy and Immunotherapy
Ann. Surg. Oncol., April 1, 2008; 15(4): 1008 - 1014.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. L. Zinzani, M. Tani, S. Fanti, V. Stefoni, G. Musuraca, P. Castellucci, E. Marchi, M. Farsad, M. Fina, C. Pellegrini, et al.
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients
Ann. Onc., April 1, 2008; 19(4): 769 - 773.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
J. W. Friedberg
Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma
Haematologica, March 1, 2008; 93(3): 336 - 338.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. J. Green, J. M. Pagel, A. Pantelias, N. Hedin, Y. Lin, D. S. Wilbur, A. Gopal, D. K. Hamlin, and O. W. Press
Pretargeted Radioimmunotherapy for B-Cell Lymphomas
Clin. Cancer Res., September 15, 2007; 13(18): 5598s - 5603s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Martin, R. R. Furman, M. Coleman, and J. P. Leonard
Phase I to III Trials of Anti B Cell Therapy in Non Hodgkin's Lymphoma
Clin. Cancer Res., September 15, 2007; 13(18): 5636s - 5642s.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. G. Gribben
How I treat indolent lymphoma
Blood, June 1, 2007; 109(11): 4617 - 4626.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Nabhan
It Is Follicular... . So, Why CHOP?
J. Clin. Oncol., March 1, 2007; 25(7): 915 - 916.
[Full Text] [PDF]

Home page
 JCOHome page
O. W. Press and R. I. Fisher
In Reply
J. Clin. Oncol., March 1, 2007; 25(7): 916 - 917.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
G. A. Salles
Clinical Features, Prognosis and Treatment of Follicular Lymphoma
Hematology, January 1, 2007; 2007(1): 216 - 225.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
D. G. Maloney
Follicular NHL: From Antibodies and Vaccines to Graft-versus-Lymphoma Effects
Hematology, January 1, 2007; 2007(1): 226 - 232.
[Abstract] [Full Text] [PDF]

<
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles